CEACAM5 and primary biliary cholangitis: Figure 2A shows that the sensitivity of CEA, CA153 and CK19-2G2 in patients with Stage II–III. CK19-2G2 levels were observed elevated in 71% MBC patients, that is almost as sensitive as CA153. Chi-Square test was used to compare the sensitivity of the three markers respectively and we found that there is no statistical difference between CK19-2G2 and other two markers respectively (P = 0.68). We found a correlation between CK19-2G2 levels and CEA (P<0.001) or CA153 (P<0.001) levels in MBC patients but not in PBC patients. (P = 0.56, P = 0.93).